Table 1.
Baseline characteristics of the study cohort.
| Age (years) | 59.5 ± 12.1 |
|---|---|
| Gender Male/Female | 106/76 |
| Body mass index (kg/m2) | 24.3 ± 3.6 |
| Type 2 DM (%) | 40 (22%) |
| Synchronous(%) | 119 (65%) |
| Chemotherapy | |
| Neoadjuvant/adjuvant/both | 35/166/28 |
| Primary tumor site* | |
| C/A/T/D/S/RS/R | 5/14/9/18/69/12/55 |
| Tumor stage T1/T2/T3/T4 | 3/22/73/84 |
| Nodal status N0/N1/N2 | 54/83/45 |
| Main tumor (cm) | 3.9 ± 2.5 |
| Tumor number1/2,3 />3 | 62/57/63 |
| CEA (ng/ml) | 178 ± 880 |
| AST (U/L) | 29 ± 13 |
| ALT (U/L) | 27 ± 22 |
| Albumin (g/dl) | 4.1 ± 0.4 |
| Platelet (103/μL) | 257 ± 98 |
| NLR | 2.9 ± 2.3 |
*C/A/T/D/S/RS/R: cecum/ascending colon/transverse colon/descending colon/sigmoid colon/recto-sigmoid colon/rectum.Abbreviation: DM, diabetes mellitus; CEA, carcinoembryonic antigen; aspartate aminotransferase; ALT, alanine aminotransferase; NLR, neutrophil-to-lymphocyte ratio.